YK-3-237

YK-3-237, a SIRT1 activator, targets mutant p53. YK-3-237 inhibits the proliferation of triple-negative breast cancer cells[1].

Product Specifications

CAS Number

[1215281-19-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Sirtuin

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/yk-3-237.html

Concentration

10mM

Purity

99.54

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

COC1=C(C=C(C=C1OC)C(/C=C/C2=CC(B(O)O)=C(C=C2)OC)=O)OC

Molecular Formula

C19H21BO7

Molecular Weight

372.18

Precautions

H302, H315, H319, H335

References & Citations

[1]Yong Weon Yi, et al. Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget. 2013 Jul;4 (7) :984-94.|[2]Murugavel Ponnusamy, et al. Activation of Sirtuin-1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis. J Pharmacol Exp Ther. 2015 Aug;354 (2) :142-51.